Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K. Terpos E, et al. Among authors: szydlo r. Leukemia. 2005 Nov;19(11):1969-76. doi: 10.1038/sj.leu.2403890. Leukemia. 2005. PMID: 16079895 Clinical Trial.
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A. Politou M, et al. Among authors: szydlo r. Br J Haematol. 2004 Sep;126(5):686-9. doi: 10.1111/j.1365-2141.2004.05092.x. Br J Haematol. 2004. PMID: 15327520 Free article.
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F. Simula MP, et al. Among authors: szydlo rm. Leukemia. 2007 May;21(5):943-8. doi: 10.1038/sj.leu.2404641. Epub 2007 Mar 15. Leukemia. 2007. PMID: 17361226
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF. Marin D, et al. Among authors: szydlo r. Leukemia. 2005 Apr;19(4):507-12. doi: 10.1038/sj.leu.2403664. Leukemia. 2005. PMID: 15703781
186 results